Pembrolizumab
Pancreatic Ductal Adenocarcinoma
Explore 280 assets in Pancreatic Ductal Adenocarcinoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
GV20 Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07623642CT.gov A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT07223047CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT07227168CT.gov A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | — | Recruiting | — | — | — |
NCT07106827CT.gov A Study of GV20-0251 in Advanced or Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06831136CT.gov Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06428409CT.gov A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | — | Recruiting | — | — | — |
NCT05482893CT.gov Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | — | Recruiting | — | — | — |
NCT05132504CT.gov Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05431270CT.gov Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | — | Recruiting | — | — | — |
NCT05403554CT.gov A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | — | Recruiting | — | — | — |
NCT04887805CT.gov Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04083599CT.gov GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03432676CT.gov Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT03727880CT.gov Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | — | Completed | — | — | — |
NCT03634332CT.gov Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | — | Unknown | — | — | — |
NCT02600949CT.gov Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | GV20 Therapeutics | P2 | CCC · 54 |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- Rmc-6236Tango Therapeutics, Inc.BB
- DaraxonrasibRevolution Medicines, Inc.BB
- S-1Genentech, Inc.BB
- MetforminBritish Columbia Cancer AgencyBB
Citation
Floatz Terminal. Pembrolizumab in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →